ReviewFrontiers in immunology2026
Glucocorticoid-induced leucine zipper as a context-dependent central integrator of innate and adaptive immune homeostasis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid-induced leucine zipper (GILZ) was originally identified as an immediate transcriptional target of glucocorticoid receptor (GR) activation and viewed primarily as a mediator of the anti-inflammatory and immunosuppressive effects of glucocorticoids (GCs). Over the last two decades, this perspective has evolved considerably, and GILZ is now recognized as a widely expressed regulatory protein in most immune cells and many non-immune tissues. In addition to GCs, anti-inflammatory cytokines, including interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), along with metabolic and tissue-derived signals, control GILZ expression. These diverse inputs suggest that GILZ acts within broad physiological networks that extend beyond traditional inflammatory pathways. GILZ's biological activities include regulating cell differentiation, survival, metabolism, tissue repair, and immune responses. Rather than acting through intrinsic enzymatic activity, GILZ exerts its effects mainly through selective interactions with transcription factors and signaling molecules. Through these interactions, it modulates how cells integrate and interpret multiple environmental and intracellular cues, thereby influencing cellular behavior in a context-dependent manner. This review integrates established and emerging evidence into a context-dependent framework for GILZ function across immune and non-immune systems. Rather than defining new functions, it examines how GILZ interactions produce distinct outcomes depending on cellular identity, tissue environment, activation state, and inflammatory timing. Emphasis is placed on immune-cell plasticity, immunometabolic adaptation, tissue homeostasis, inflammation resolution, and their implications for the therapeutic potential and limitations of GILZ modulation. We propose that the biological significance of GILZ is best understood, not as that of a master suppressor of immunity, but as a context-dependent integrator that helps determine how cells transition between inflammatory, regulatory, reparative, and homeostatic states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.